All In Biotech

Free tool

FAERS Monitor: Jemperli

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761223 or its brand name (Jemperli, Dostarlimab-Gxly). Reports on generic versions are filed under their own applications.

Reports

2,493

Serious

2,141

86% of reports

Hospitalization

965

Death reported

296

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • malignant neoplasm progression254
  • off label use145
  • fatigue133
  • rash114
  • anaemia98
  • arthralgia87
  • diarrhoea87
  • death84
  • neuropathy peripheral82
  • thrombocytopenia80
  • nausea70
  • hypothyroidism66
  • product use in unapproved indication64
  • pyrexia62
  • neutropenia60

Reports by year received

View as table
YearReports
20182
20199
202040
2021188
2022174
2023171
2024422
2025742
2026745

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,666 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
malignant neoplasm progressionSignal25421.018.74,823
hypothyroidismSignal6617.513.81,008
neuropathy peripheralSignal827.35.9439
thrombocytopeniaSignal806.04.9333
anaemiaSignal984.33.6250
neutropeniaSignal603.72.9118
rashSignal1142.21.876
product use in unapproved indicationSignal642.21.740
arthralgia871.81.429
pyrexia621.51.210
fatigue1331.41.218
off label use1451.41.217
diarrhoea871.10.91
death840.80.73
nausea700.70.66

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.